Portal hypertension

Current Opinion in Gastroenterology

Volumn 18, Issue 3, 2002, Pages 351-359

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; DIURETIC AGENT; IRBESARTAN; ISOSORBIDE MONONITRATE; LOSARTAN; NEUROTOXIN; OCTREOTIDE; PROPRANOLOL; SOMATOSTATIN; TERLIPRESSIN; VAPREOTIDE; VASOCONSTRICTOR AGENT;

ASCITES; BACTERIAL PERITONITIS; BRAIN DISEASE; CLINICAL TRIAL; HEPATORENAL SYNDROME; HUMAN; HYDROTHORAX; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; REVIEW; SCLEROTHERAPY; VARICOSIS; VASODILATATION;

EID: 0036223815     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200205000-00009     Document Type: Review

References (51)

1. Current management of the complications of cirrhosis and portal hypertension: Varices and variceal hemorrhage, ascites and spontaneous bacterial peritonitis
2. Overexpression of endothelin-1 in bile duct ligated rats: Correlation with activation of hepatic stellate cells and portal pressure
3. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo
4. Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver
5. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats
6. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension
7. Neuronal nitric oxide synthase and systemic vasodilatation in rats with cirrhosis
8. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis
9. Portal hypertension and the hyperdynamic circulation: Nitric oxide in a haze of cannabinoid smoke
10. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis
11. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis
12. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension
13. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices: Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study
14. Prognostic indicators of risk for first variceal bleeding in cirrhosis: A multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) Index
15. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding
16. Pharmacological treatment of portal hypertension: An evidence-based approach
17. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers
18. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs
19. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats
20. Terlipressin for acute esophageal variceal hemorrhage
21. Octreotide for acute esophageal variceal bleeding: A meta-analysis
22. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats
23. Desensitization to the effects of intravenous octreotide in patients with cirrhosis with portal hypertension
24. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during active variceal bleeding
25. Early administration of vapreotide for variceal bleeding in patients with cirrhosis
26. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices
27. Transjugular intrahepatic portosystemic shunt vs small-diameter prosthetic H-graft portocaval shunt: Extended follow-up of an expanded randomized prospective trial
28. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: A randomised trial
29. The natural history of portal hypertensive gastropathy: Influence of variceal eradication
30. The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: A prospective, controlled trial
31. Furosemide-induced natriuresis as a test of identify patients with cirrhosis with refractory ascites
32. Effects of ascites resolution after successful TIPS on nutrition in patients with cirrhosis with refractory ascites
33. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: Long-term results in 40 patients
34. Successful treatment of hepatic hydrothorax with octreotide
35. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis
36. Long-term terlipressin administration improves renal function in patients with cirrhosis with type I hepatorenal syndrome: A pilot study
37. Bacterial infection in patients with cirrhosis and its relationship with alcohol
38. Bacterial infection in patients with advanced cirrhosis: A multicentre prospective study
39. Spontaneous bacterial peritonitis: Inhospital mortality, predictors of survival, and health care costs from 1988 to 1998
40. Carriage of Staphylococcus aureus and of gram-negative bacilli resistant to third-generation cephalosporins in patients with cirrhosis: A prospective assessment of hospital-acquired infections
41. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consensus document
42. The value of ascitic fluid polymorphonuclear cell count determination during therapy of spontaneous bacterial peritonitis in patients with liver cirrhosis
43. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation
44. Neurotransmitter dysfunction in hepatic encephalopathy: New approaches and new findings
45. Identification of osmosensitive and ammonia-regulated genes in rat astrocytes by Northern blotting and differential display reverse transcriptase-polymerase chain reaction
46. Increased density of brain histamine H(1) receptors in rats with portacaval anastomosis and in patients with cirrhosis with chronic hepatic encephalopathy
47. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation
48. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy
49. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis
50. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure
51. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure